Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
연구 개요
상세 설명
The objective of the study is to determine the effect suzetrigine has on postoperative pain, opioid use, sleep quality, and patient satisfaction when it is used as part of a multimodal pain regimen prescribed to patients after total knee arthroplasty.
The study will enroll eligible participants who are scheduled to receive a total knee arthroplasty. Participants will first consent to participate in the research study. They will then be asked to complete certain baseline measurements and instructed to begin wearing a device on their wrist that will quantify their activity and sleep quality ("sleep tracker"). They will complete a baseline KOOS JR survey. There are no additional surveys or diaries to complete pre-operatively. They will receive a suzetrigine prescription (the intervention) on the day of their total knee arthroplasty after the procedure has been completed in addition to the standard of care pain control regimen after surgery. They will complete a diary for a set time after surgery, and subject will continue to wear the sleep tracker for up to 2 weeks post-surgery. They will complete a daily sleep diary for 14 days after surgery to document sleep duration, sleep quality, nighttime awakenings, and other related factors. They will also complete a diary for 14 days after surgery that asks them to report their pain level 3 times daily, their nausea level 3 times daily, and the number of narcotic pills taken daily, and continue to wear their activity and sleep tracker. They will be asked to complete a pill tracking chart to confirm they are taking Journavx as directed for 14 days after surgery. 1 week and 2 weeks after surgery, they will complete a survey that quantifies their sleep related impairment. Approximately 3 months after surgery, subjects will complete another survey. Participants will have interactions with the study team until approximately 3 months after surgery.
연구 유형
등록 (추정된)
단계
- 4단계
연락처 및 위치
연구 연락처
- 이름: Darrell Favors
- 전화번호: 404-313-3276
- 이메일: darrell.favors@emory.edu
연구 장소
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory Clinic
-
Atlanta, Georgia, 미국, 30329
- Emory Clinic at Executive Park
-
Atlanta, Georgia, 미국, 30329
- Emory Orthopaedics and Spine Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee.
- Patients between the ages of 18 and 95 years.
Exclusion Criteria:
- Patients with concurrent and significant injuries to other bones or organs.
- Patients with local infections.
- Minors unable to provide informed consent for participation in the study.
- Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures.
- Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk.
- Patients with preoperative opioid use, defined as daily use less than 4 weeks before the index surgery.
- Patients with a history of severe heart disease (NYHA2), renal failure, or liver dysfunction
- Patients with active peptic ulcer disease.
- Patients neurological or psychiatric diseases, potentially influencing pain perception
- Patients who are pregnant.
- Patients with a history of alcohol or medical abuse, allergies to glucocorticoids, current daily use of glucocorticoids.
- Patients who are unable to take NSAIDs.
- Patients who receive Deep Venous Thrombosis (DVT) prophylaxis different than Aspirin (81mg) twice daily (BID).
- Patients who have known diabetes mellitus as defined with an A1C greater than 6.5%.
- Patients currently taking CYP3A inhibitors
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Suzetrigine Regimen Arm
Suzetrigine (JOURNAVX®) administered orally consisting of a course that lasts up to a maximum of 14 days. The starting dose will be 100 mg orally taken as two 50 mg tablets on an empty stomach (at least 1 hour before or 2 hours after food). Maintenance dosing will begin 12 hours after the initial dose, at which point patients will take 50 mg orally every 12 hours. |
Suzetrigine is an orally administered, selective NaV1.8 voltage-gated sodium channel inhibitor being investigated as a non-opioid analgesic for the treatment of pain through inhibition of pain signal transmission in peripheral sensory neurons.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Mean pain intensity score on the Numeric Rating Scale (NRS)
기간: Day 0-14 postoperative
|
Pain will be measured using a scale from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, using a Visual Analog Pain Scale (VAS-pain).
Higher score correlates with worse outcome.
|
Day 0-14 postoperative
|
|
Average daily opioid consumption
기간: Day 0-14 postoperative
|
Postoperative opioid consumption will be quantified in morphine milligram equivalents (MME) during postoperative days 0-14.
|
Day 0-14 postoperative
|
|
Cumulative opioid consumption
기간: 3 weeks and 3 months postoperative
|
Postoperative opioid consumption will be quantified as cumulative MME at 3 weeks and 3 months.
|
3 weeks and 3 months postoperative
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Nausea scores postoperative
기간: Day 0-14 post-operative
|
A nausea assessment will be assessed using the Visual Analog Nausea Scale (VAS-nausea), which is ranked from 0 (no nausea) to 10 (highest amount of nausea).
Patients will be asked to fill out the VAS-nausea each day until post-operative day 14.
|
Day 0-14 post-operative
|
|
Total sleep time
기간: Day 0-14 post-operative
|
Total sleep time will be collected using actigraphy during postoperative days 0-14.
|
Day 0-14 post-operative
|
|
Sleep efficiency
기간: Day 0-14 post-operative
|
Sleep efficiency will be measured by recording the ratio of time asleep to time in bed, using actigraphy during postoperative days 0-14.
|
Day 0-14 post-operative
|
|
Sleep latency
기간: Day 0-14 post-operative
|
Sleep latency will be measured by recording the time from "lights out" to sleep onset, using actigraphy during postoperative days 0-14.
|
Day 0-14 post-operative
|
|
Wake after sleep onset (WASO)
기간: Day 0-14 post-operative
|
Wake after sleep onset (WASO) will be assessed using actigraphy during postoperative days 0-14.
|
Day 0-14 post-operative
|
|
EQ5D Score
기간: 3 months post-operative
|
Health-related quality of life measure using the EQ-5D questionnaire, which assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Responses are converted into a summary index score, where 1 represents full health and 0 represents death (higher values indicating better health status).
|
3 months post-operative
|
|
KOOS Jr Score
기간: Baseline, 3 months post-operative
|
Patient-reported knee function assessed using the Knee Injury and Osteoarthritis Outcome Score Junior (KOOS Jr).
The KOOS Jr is a validated short-form instrument derived from the full KOOS, designed to evaluate knee health based on key items related to pain, symptoms, and physical function.
Scores are transformed to a 0 to 100 scale, with higher scores indicating better knee function and fewer symptoms.
|
Baseline, 3 months post-operative
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Ajay Premkumar, MD, Emory University
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .